Author:
Schreurs Marco W. J.,de Vries Annick
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Darrouxain F, Bian S, Desvignes C, et al. Immunoassays for measuring serum concentrations of monoclonal antibodies and anti-biopharmaceutical antibodies in patients. Ther Drug Monit. 2017;39:316–21.
2. L’Ami MJ, Krieckaert CL, Nurmohamed MT, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2017;
https://doi.org/10.1136/annrheumdis-2017-211781
.
3. Qu M, An B, Shen S, et al. Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry. Mass Spectrom Rev. 2017;36(6):734–54.
4. Committee for Medicinal Products for Human Use. EMEA guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. 2005.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003031.pdf
. Geraadpleegd op: 7 jun 2017.
5. Caldano M, Raoul W, Rispens T, et al. Drug efficacy monitoring in pharmacotherapy of multiple sclerosis with biological agents. Ther Drug Monit. 2017;39:350–5.